Oncogenic mutations in p53 inhibit T-cell tumor recognition through enhanced PD-L1 and PD-L2 tumor cell expression, thereby inhibiting T-cell immune recognition [[60], [61], [62]]. This evidence concerns the gene TP53 and neoplasm.